Methods of Treating Viral Associated Diseases

• US 20150141375A1
• Filed: 11/14/2014
• Published: 05/21/2015
• Est. Priority Date: 10/30/2009
• Status: Abandoned Application

• Current Assignee: Chimerix Incorporated
• Original Assignee: Chimerix Incorporated
• Inventors: Painter, George R., Lanier, Ernest Randall, Painter, Gwendolyn
• Application Number:
  US14/542,295
• Publication Number:
  US 20150141375A1
• Time in Patent Office: Days
• US Class Current: 514/81
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods may further comprise at least one immunosuppressant agent to treat diseases associated with at least one virus of a subject in need of immunosuppressant agents.

Claims

1. A method of treating ebola virus in a subject, comprising administering to the subject a therapeutically effective amount of a compound selected from

2. The method of claim 1, wherein the compound specifically targets viral infected cells and/or viral replications.

3. The method of claim 1, wherein the subject has previously been treated with at least one antiviral agent and the previous treatment has failed.

4. The method of claim 3, wherein the antiviral agent the subject has previously been treated with is selected from the group consisting of cidofovir, ganciclovir, valganciclovir, foscarnet, acyclovir, valganciclovir, and a combination thereof.

5. The method of claim 1, wherein the compound is

6. The method of claim 1, wherein the compound is

7. The method of claim 1, wherein the compound is administered at a dosage of about 1 mg/kg once weekly to about 4 mg/kg twice weekly.

8. A method for the prophylactic treatment of a subject uninfected with ebola virus, comprising administering to the subject a therapeutically effective amount of a compound selected from

9. The method of claim 8, wherein the compound is administered at a dosage of about 1 mg/kg once weekly to about 4 mg/kg twice weekly.

10. The method of claim 8, wherein the compound is

11. The method of claim 8, wherein the subject is at high risk of exposure to the ebola virus.

12. The method of claim 11, wherein the compound is administered 6 hours pre-exposure.

13. The method of claim 11, wherein the compound is administered 24 hours pre-exposure.

14. The method of claim 11, wherein the compound is administered 48 hours pre-exposure.